Skip to content

Cullinan Therapeutics, Inc. CGEM Non-Controlling Interests

Non-Controlling Interests at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$880K-7.3%

Other financials

Income statement

See full
Revenue-
Operating income-$53.7M+2.4%
Net income-$49.7M-2.4%
EPS (diluted)-$0.69+24.2%

Balance sheet

See full
Cash & equivalents$75.1M-2.1%
Total debt$2.4M+29.5%
Total equity$408.7M-30.8%
Total assets$403.0M-30.5%

Cash flow

See full
Operating cash flow-$46.0M-6.7%
CapEx$11.0K
Free cash flow-$38.1M-4.1%

Valuation

See full
Market cap$1.08B+151%
Enterprise value$1.01B+181%

Profitability

See full
Operating margin-358.7%
Net margin-346.1%

Returns & leverage

See full
Return on equity-44%+26.2pp
Debt / equity0.0×
Current ratio10.3×-1.3×

Where this comes from

Reported directly by Cullinan Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:MinorityInterest.

The official record: Cullinan Therapeutics, Inc.’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cullinan Therapeutics, Inc.'s non-controlling interests.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cullinan Therapeutics, Inc.'s non-controlling interests?
Cullinan Therapeutics, Inc. (CGEM) reported non-controlling interests of $0 in Q4 2025.
What is the long-term trend for Cullinan Therapeutics, Inc.'s non-controlling interests?
Over 5 years (2020 to 2025), Cullinan Therapeutics, Inc.'s non-controlling interests has grown at a -100.0% compound annual growth rate (CAGR), from $1.3M to $0.
What does non-controlling interests mean?
Equity attributable to minority shareholders in subsidiaries not fully owned by the parent — their proportional claim on subsidiary net assets.